Cross-resistance Pattern of Cell Lines Selected for Resistance Towards Different Cytotoxic Drugs to Membrane-toxic Phospholipids in Vitro

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1990 Jan 1

PMID 2225315

Citations 5

Authors

A W Himmelmann

G Steinhauser

R Busch

E J MODEST

A Noseda

J Rastetter

W R VOGLER

W E Berdel

Affiliations

Soon will be listed here.

Abstract

The synthetic ether lipids ET-18-OCH3 and BM41.440 and a derivative, hexadecylphosphocholine, were tested for inhibition of [3H]-thymidine uptake into a Chinese hamster ovarian cell line (AUXBl) and its multidrug-resistant subline selected for colchicine resistance (CHRC5). The activity of all three compounds against the multidrug-resistant subline was equal to or higher than that against the parent line. The same result was found for their activity against a human leukemic lymphoblastic cell line (CEM/O) and its methotrexate-resistant subline (CEM/MTX). In contrast, two multidrug-resistant cell lines selected for resistance to Adriamycin, the mouse leukemia cell line P388/ADR and the murine sarcoma cell line S180/ADR, expressed modest cross-resistance to the lipids as measured by thymidine uptake. Experiments performed using the trypan-blue dye-exclusion assay yielded comparable results, although this system revealed a slightly different sensitivity in showing the cytotoxicity of the drugs. By this assay, modest cross-resistance for ET-18-OCH3 and BM41.440 to Adriamycin was found only after 24 h incubation and decreased after 48 h incubation, with almost equal sensitivity to both drugs being shown by the parental (P388/W) and resistant lines (P388/ADR). Furthermore, findings from a human tumor-cloning assay were in accordance with these data, although they did not indicate cross-resistance for the P388/ADR cell line. These results suggest that certain ether lipids and derivatives might represent valuable anticancer drugs warranting further study in the setting of resistant disease.

Citing Articles

Evaluation of in vitro and in vivo anti-inflammatory activity of biologically active phospholipids with anti-neoplastic potential in porcine model.

Vicenova M, Nechvatalova K, Chlebova K, Kucerova Z, Leva L, Stepanova H BMC Complement Altern Med. 2014; 14:339.

PMID: 25234616 PMC: 4179840. DOI: 10.1186/1472-6882-14-339.

MDR1 causes resistance to the antitumour drug miltefosine.

Rybczynska M, Liu R, Lu P, Sharom F, Steinfels E, Pietro A Br J Cancer. 2001; 84(10):1405-11.

PMID: 11355955 PMC: 2363649. DOI: 10.1054/bjoc.2001.1776.

Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).

Hofmann J, Utz I, Spitaler M, Hofer S, Rybczynska M, Beck W Br J Cancer. 1997; 76(7):862-9.

PMID: 9328144 PMC: 2228059. DOI: 10.1038/bjc.1997.476.

Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.

Small G, Strum J, Daniel L Lipids. 1997; 32(7):715-23.

PMID: 9252959 DOI: 10.1007/s11745-997-0091-3.

Membrane-interactive lipids as experimental anticancer drugs.

Berdel W Br J Cancer. 1991; 64(2):208-11.

PMID: 1892746 PMC: 1977494. DOI: 10.1038/bjc.1991.277.

References

Moscow J, Cowan K . Multidrug resistance. J Natl Cancer Inst. 1988; 80(1):14-20. DOI: 10.1093/jnci/80.1.14. View

Rosowsky A, Lazarus H, Yuan G, Beltz W, Mangini L, Abelson H . Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts. Biochem Pharmacol. 1980; 29(4):648-52. DOI: 10.1016/0006-2952(80)90391-3. View

Noseda A, Berens M, Piantadosi C, MODEST E . Neoplastic cell inhibition with new ether lipid analogs. Lipids. 1987; 22(11):878-83. DOI: 10.1007/BF02535548. View

Siegfried J, Tritton T, Sartorelli A . Comparison of anthracycline concentrations in S180 cell lines of varying sensitivity. Eur J Cancer Clin Oncol. 1983; 19(8):1133-41. DOI: 10.1016/0277-5379(83)90039-1. View

Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y . Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982; 42(11):4730-3. View

Schimke R . Gene amplification in cultured animal cells. Cell. 1984; 37(3):705-13. DOI: 10.1016/0092-8674(84)90406-9. View

Daniel L, Small G, SCHMITT J, Marasco C, Ishaq K, Piantadosi C . Alkyl-linked diglycerides inhibit protein kinase C activation by diacylglycerols. Biochem Biophys Res Commun. 1988; 151(1):291-7. DOI: 10.1016/0006-291x(88)90592-x. View

Akiyama S, Cornwell M, Kuwano M, Pastan I, Gottesman M . Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol. 1988; 33(2):144-7. View

Chabner B, Gottesman M . Meeting highlights: William Guy Forbeck Foundation think tank on "multidrug resistance in cancer chemotherapy". J Natl Cancer Inst. 1988; 80(6):391-4. DOI: 10.1093/jnci/80.6.391. View

10.

Haber D, Schimke R . Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell. 1981; 26(3 Pt 1):355-62. DOI: 10.1016/0092-8674(81)90204-x. View

11.

Berger M, MUNDER P, Schmahl D, Westphal O . Influence of the alkyllysophospholipid ET-18-OCH3 on methylnitrosourea-induced rat mammary carcinomas. Oncology. 1984; 41(2):109-13. DOI: 10.1159/000225803. View

12.

Fojo A, Akiyama S, Gottesman M, Pastan I . Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985; 45(7):3002-7. View

13.

Beck W . Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. Cancer Treat Rep. 1983; 67(10):875-82. View

14.

Johnson R, Chitnis M, Embrey W, Gregory E . In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep. 1978; 62(10):1535-47. View

15.

Noseda A, White J, Godwin P, Jerome W, MODEST E . Membrane damage in leukemic cells induced by ether and ester lipids: an electron microscopic study. Exp Mol Pathol. 1989; 50(1):69-83. DOI: 10.1016/0014-4800(89)90057-9. View

16.

Pastan I, Gottesman M . Multiple-drug resistance in human cancer. N Engl J Med. 1987; 316(22):1388-93. DOI: 10.1056/NEJM198705283162207. View

17.

Berdel W, Fromm M, Fink U, Pahlke W, Bicker U, Reichert A . Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin. Cancer Res. 1983; 43(11):5538-43. View

18.

Herrmann D, Neumann H, Berdel W, Heim M, Fromm M, Boerner D . Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients. Lipids. 1987; 22(11):962-6. DOI: 10.1007/BF02535565. View

19.

Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H . Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur J Cancer Clin Oncol. 1988; 24(9):1457-61. DOI: 10.1016/0277-5379(88)90336-7. View

20.

Berdel W, Bausert W, Weltzien H, Modolell M, Widmann K, MUNDER P . The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur J Cancer (1965). 1980; 16(9):1199-204. DOI: 10.1016/0014-2964(80)90179-6. View